We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Potential of Gene Therapy for Treating Hemophilia Demonstrated in Dog Model

By LabMedica International staff writers
Posted on 02 Feb 2016
Print article
Image: Molecular model of coagulation Factor VII (Photo courtesy of Wikimedia Commons).
Image: Molecular model of coagulation Factor VII (Photo courtesy of Wikimedia Commons).
A gene therapy approach was shown to cure a form of hemophilia caused by deficiency of the Factor VII coagulation protein in a dog model system.

Factor VII (FVII) deficiency is a rare autosomal recessive bleeding disorder treated by infusion of fresh-frozen plasma, plasma-derived FVII concentrates, and low-dose recombinant activated FVII. Clinical data have suggested that a mild elevation of plasma FVII levels results in improved clotting behavior.

Research dogs with a G96E missense FVII mutation (FVII-G96E) have less than 1% of normal FVII activity. Investigators at the University of North Carolina (Chapel Hill, USA) and The Children’s Hospital of Philadelphia (PA, USA) used the Western blot technique to show that these dogs had undetectable plasmatic antigen, and thus represented the most prevalent type of human FVII deficiency (low antigen/activity).

The investigators treated these animals by gene therapy using liver-directed, Adeno-associated viral (AAV) serotype VIII vector delivery of a canine FVII zymogen transgene (cFVII). The group of four dogs received escalating AAV doses.

Results published in the December 23, 2015, online edition of the journal Blood revealed that therapeutic expression of the gene (15% of normal) was attained and was stable for more than one year (ongoing) without antibody formation to the cFVII transgene. A level of gene expression more that 770% of normal was found in the dog receiving the highest AAV dose.

No evidence of pathological activation of coagulation or detrimental animal physiology was observed as platelet counts, D-dimer, fibrinogen levels, and serum chemistries remained normal in all dogs (cumulative 6.4 years). A transient and non-inhibitory IgG2 response against cFVII was seen only in the dog receiving the highest AAV dose.

“For many people living in the developing world, constant injections are not practical or at least not feasible right now; but a single injection could be,” said contributing author Dr. Tim Nichols, professor of medicine and pathology at the University of North Carolina. “We have now shown that this treatment is safe and effective for dogs with inherited factor VII deficiency. This is exciting because our other gene therapy work on bleeding disorders, such as hemophilia, has demonstrated that safety and efficacy in dogs has translated well in human clinical trials.”

Related Links:

University of North Carolina
The Children’s Hospital of Philadelphia


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.